Overview

Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
0
Participant gender:
All
Summary
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rambam Health Care Campus
Treatments:
Camptothecin
Gemcitabine
Irinotecan
Criteria
Inclusion Criteria:

- locally advanced pancreatic cancer

- performance status 0-2

- normal blood count and chemistry

- no previous chemotherapy or radiotherapy

Exclusion Criteria:

- serious concurrent systemic disease